Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice

CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.PMID:38597096 | DOI:10.1111/ajd.14267

Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Guiovana Fernanda Osorio-G ómez Juan Ortiz- Álvarez Delia Diaz-Ceca Cesar Guijarro-S ánchez Juli án Conejo-Mir Sánchez Pablo Fern ández Crehuet Source Type: research